Skip to main content
Contact Us
Subscribe
E-Edition
84°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pliant Therapeutics Inc
(NQ:
PLRX
)
11.53
+0.41 (+3.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pliant Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To Know
February 05, 2024
Via
Benzinga
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
February 04, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
November 13, 2023
INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
The Latest Analyst Ratings for Pliant Therapeutics
November 10, 2023
Via
Benzinga
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Conferences
November 08, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
November 06, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Where Pliant Therapeutics Stands With Analysts
October 04, 2023
Via
Benzinga
Expert Ratings for Pliant Therapeutics
September 15, 2023
Via
Benzinga
Where Pliant Therapeutics Stands With Analysts
August 22, 2023
Via
Benzinga
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
October 31, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
October 19, 2023
Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
October 16, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday
September 27, 2023
Keybanc cut the price target for Danaher Corporation (NYSE: DHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market...
Via
Benzinga
Pliant Therapeutics Reveals Encouraging Data From Liver Disease Trial
September 26, 2023
Pliant Therapeutics Inc (NASDAQ: PLRX) announced data from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected
Via
Benzinga
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 26, 2023
Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi...
Via
Benzinga
Why Shares of Pliant Therapeutics Are Rising Tuesday
September 26, 2023
The company's lead therapy fared well in a phase 2a trial to treat two separate conditions.
Via
The Motley Fool
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
September 26, 2023
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
September 26, 2023
Pre-market stock movers are among the biggest topics worth checking out on Tuesday and we have the latest news for investors!
Via
InvestorPlace
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
September 26, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
September 25, 2023
Via
Benzinga
Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
September 25, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
September 15, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
September 15, 2023
Friday's session saw 169 companies set new 52-week lows.
Via
Benzinga
Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
September 11, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis – Could GRI-0621 Be The Solution?
August 31, 2023
Idiopathic Pulmonary Fibrosis (IPF) is a serious chronic lung disease characterized by the thickening and stiffening of the lung tissue surrounding the air sacs. The exact cause of IPF is unknown, but...
Via
Benzinga
Pliant Therapeutics to Participate in Upcoming Investor Conferences
August 30, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023
August 28, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
August 17, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.